- In March 2024, AbbVie Inc., a global leader in immunology, announced the U.S. FDA approval of Rinvoq (upadacitinib) for the treatment of non-radiographic axial spondyloarthritis. This approval expands the drug’s label and reflects AbbVie’s ongoing commitment to developing targeted therapies for a wide range of arthritis-related conditions. By providing new treatment options for previously underserved patient populations, AbbVie continues to strengthen its leadership in the U.S. arthritis therapeutics landscape
- In February 2024, Pfizer Inc. launched an expanded patient support program for its rheumatoid arthritis drug Xeljanz in the U.S., aimed at improving treatment adherence and affordability. The program includes co-pay assistance, remote nurse support, and educational tools, highlighting Pfizer’s patient-centric approach to chronic disease management and its focus on enhancing the treatment experience in real-world settings
- In January 2024, Amgen Inc. reported positive Phase 3 clinical trial results for its investigational biosimilar to adalimumab (a reference to Humira), signaling a key step toward broader access and cost reduction for U.S. arthritis patients. The biosimilar demonstrated comparable efficacy and safety, supporting Amgen’s strategy to strengthen its presence in the growing biosimilars segment of the arthritis market
- In December 2023, Johnson & Johnson’s Janssen division launched a new awareness campaign titled “Move Without Pain” across major U.S. cities, promoting early diagnosis and advanced treatment options for psoriatic arthritis. The initiative, involving healthcare professionals and patient influencers, aims to reduce diagnosis delays and promote the role of biologics and targeted therapies in long-term disease management
- In November 2023, Eli Lilly and Company received U.S. FDA fast track designation for its investigational monoclonal antibody therapy targeting interleukin-17 in patients with active ankylosing spondylitis. This regulatory milestone underscores Lilly’s commitment to expanding its immunology portfolio and addressing unmet needs within the arthritis community through precision medicine and accelerated innovation
